ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… RNA therapy Find out how RNA therapy works, how it differs … RNA therapies being used to treat patients today. Axiomer™ RNAediting technology Axiomer™ RNAediting technology Scientists …
… diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding ProQR, … for the ADAR enzymes responsible for adenosine to inosine RNAediting in humans. In addition, his group has led in the …
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNAediting technology development. This platform technology …
Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
